Tech Company Financing Transactions
Century Therapeutics Funding Round
On 3/4/2021, Century Therapeutics secured $160 million in Series C funding from Casdin Capital, Avidity Partners and Federated Kaufmann Funds.
Transaction Overview
Company Name
Announced On
3/4/2021
Transaction Type
Venture Equity
Amount
$160,000,000
Round
Series C
Investors
Proceeds Purpose
Funds raised will help advance Century's rich pre-clinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3675 Market St.
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Century Therapeutics is developing novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies. Our commitment to developing accessible cell therapies provides an unparalleled opportunity to advance the course of cancer care.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lalo Flores
Chief Scientific Officer
Luis Borges
Chief Technical Officer
Gregory Russotti
Vice President
Kenneth Dow
VP - Bus. Development
Janelle Anderson
VP - Bus. Development
Michael Diem
VP - Bus. Development
Adrienne Farid
VP - Engineering
Michael Naso
VP - Finance
Douglas Carr
VP - Human Resources
Shane Williams
VP - Manufacturing
Carl Burke
VP - R & D
Hy Levitsky
Browse more venture capital transactions:
Prev: 3/4/2021: Retail Zipline venture capital transaction
Next: 3/4/2021: TaxBit venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions on this site are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs